Phase 3 Post Hoc Analysis Shows Foslevodopa/Foscarbidopa Reduces Troublesome Dyskinesia in Advanced Parkinson Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.

Reducing dyskinesia in advanced #PD 🧠

🆕 phase 3 post hoc data show foslevodopa foscarbidopa led to elimination of troublesome dyskinesia in many patients 📉

A meaningful step toward improving daily function 💪

More from #AAN2026 👇
www.neurologylive.com/view/phase-3...
#Parkinson #Neurology #AANAM

Excited for my first #AANAM!

Come chat at my posters Sunday!

P1 8-9am: morphometric differences from typical development after left but not right pediatric resection

P2 11:45am-12:45pm: characterization/prediction of functional outcomes after pediatric hemispheric surgery

@aanmember.bsky.social

#AANAM Day 2 wrap up!

Tim Miller received the Potamkin Prize; Eric Landsness won the Sleep Medicine Investigator Award, and Yan Wang won the Stroke Leadership Prize!

Presenters: Suzanne Schindler, Eric McDade, Beau Ances and Jorge Llibre-Guerra, Eva Klinman (poster)

Dr. Tracy Milligan from NYMC receiving the A.B. Baker Award for Lifetime Achievement in Neurologic Education and delivering her Keynote Address, “The Neurology Family Tree and Helping Others Thrive,” at the @aanmember.bsky.social #AANAM speaking to the power of mentorship from childhood onwards: 🧠 🦉

Fantastic start to #AANAM at the Controversies in Neurology Plenary

Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis | NeurologyLive - Clinical Neurology News and Neurology Expert Insights A phase 3, double-blind study is assessing telitacicept in generalized myasthenia gravis, following prior trials that demonstrated substantial improvements in functional and strength-based clinical ou...

A novel mechanism enters the spotlight in gMG

🌍📊 Telitacicept is now being evaluated in a global #Phase3 trial—targeting both BAFF & APRIL to reduce autoantibody production 🔬

More from #AANAM 👇
www.neurologylive.com/view/telitac...
#Neurology #ClinicalTrials #gMG #BrainHealth

The 2026 #AANAM has begun—and NeurologyLive is covering it all❗

🧠 From late-breaking data to expert perspectives, we’ve got you covered.

Follow along to with all our coverage here: www.neurologylive.com/conferences/...
#Neurology #AnnualMeeting #AmericanAcademyNeurology #BrainHealth #Neuro

Solriamfetol Shows No Significant Impact on Nocturnal Sleep Parameters in OSA-Related Excessive Daytime Sleepiness | NeurologyLive - Clinical Neurology News and Neurology Expert Insights An exploratory analysis of a phase 3 trial showed that solriamfetol improved daytime wakefulness without producing consistent or clinically meaningful changes in nocturnal sleep quality measures.

Wakefulness without compromise? 👀

New phase 3️⃣ data suggest solriamfetol improves daytime sleepiness in #OSA—without meaningful disruption to nighttime sleep.

A key consideration for clinicians balancing EDS treatment and sleep quality.

Read more 👇
www.neurologylive.com/view/solriam...
#Neurology

Advancing Brain Injury Rehabilitation Through Technology and Continuum of Care | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Erika Trovato, MD, associate chief medical officer at Burke Rehabilitation Hospital in New York, discusses interdisciplinary rehabilitation, emerging technologies, and the evolving focus on long-term ...

Brain injury care doesn’t stop at discharge 🧠

In this Q&A, Erika Trovato, DO, MS, highlights:
🔹 Interdisciplinary rehab
🔹 Emerging tech like neuromodulation
🔹 The importance of long-term + caregiver support

Read more 👉 www.neurologylive.com/view/advanci...
#Neurology #TBI #Rehab #BrainHealth

MOGAD Awareness Month: From Emerging Entity to Evolving Clinical Priority | NeurologyLive - Clinical Neurology News and Neurology Expert Insights MOGAD Awareness Month highlights the evolution of myelin oligodendrocyte glycoprotein antibody–associated disease from a once-misclassified condition to a distinct neuroimmunologic disorder.

🧠 April is #MOGAD Awareness Month

Once misclassified as MS or NMOSD, MOGAD is now recognized as a distinct neuroimmunologic disease—thanks in part to advances in cell-based antibody assays 🔬

Awareness = better diagnosis + better care
Read more here: www.neurologylive.com/view/mogad-a...
#Neurology

🏆 And your #NeuroMadness Champion is…

#1 Natalizumab 🎉

After weeks of matchups, debates, and votes, one rose above the rest to snag the crown 👑

A true game-changer in neurology— big thanks to everyone who followed along and voted! Until next year!
#Neurology #MarchMadness #MedTwitter #March

Frontlines with Frontera: Detecting Consciousness Beyond the Bedside Exam | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you a 2-part exclusive interview with Brian Edlow, MD, of Mass General Brigham. [LISTEN TIME: 26 minutes]

What if consciousness isn’t always visible at the bedside? 👀

🎙️ Jennifer Frontera, MD, and Brian Edlow, MD, explore covert consciousness, advanced EEG/fMRI, and what it means for ICU decision-making

🧠 A must-listen for clinicians
⏱️ Part-1: 26 min
🔗 👉 www.neurologylive.com/view/frontli...
#Neurology

Updated Meta-Analysis Reinforces Short-Term Efficacy of Modafinil for Excessive Daytime Sleepiness in Narcolepsy | NeurologyLive - Clinical Neurology News and Neurology Expert Insights A meta-analysis of randomized trials confirmed modafinil improves both objective and subjective measures of daytime sleepiness in narcolepsy.

📊 Researchers found Modafinil significantly improves both objective and subjective sleepiness measures in #Narcolepsy

🧠 5 RCTs | 997 patients
⚡ Longer wakefulness on MWT
📉 Lower #ESS scores

These findings highlight a gap in randomized trials

More ➡️ www.neurologylive.com/view/updated...
#Neurology

Q1 2026 Clinical Recap: 7 FDA-Approved Treatments for Neurologists to Know | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

🧠 Miss any FDA neurology approvals in Q1?

NeurologyLive® rounded up key regulatory decisions from Q1 clinicians should know, from the first pediatric Menkes disease therapy to a higher-dose regimen of Nusinersen.

See the full recap 👇
www.neurologylive.com/view/q1-2026...
#Neurology #FDA #MS

👀 In case you missed it…

NeurologyLive® hosted a roundtable exploring the 2026 acute ischemic stroke guidelines with Andrei Alexandrov, MD, and Beth Cavanaugh, MD who break down what these updates mean for #StrokeCare

Watch the discussion 🎥
www.neurologylive.com/roundtable-d...
#Stroke #Neurology

🧠 Could high-intensity inpatient rehabilitation improve outcomes in PD?

Steven Markos, MD, discusses a 2-week interdisciplinary rehab program that showed improvements in mobility, daily function, and vocal outcomes for patients with PD

Read more:
www.neurologylive.com/view/rethink...
#Neurology

Episode 163: The Clinical Reality of Seronegative Myasthenia Gravis | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sarah Hoffmann, MD, PhD. [LISTEN TIME: 15 minutes]

Our latest Mind Moments dives into the real-world challenges of diagnosing and treating seronegative gMG with Sarah Hoffmann, MD

👉 Why diagnosis isn’t always straightforward
👉 Why some patients need reevaluation
👉 Why trials in this space remain difficult

📲 www.neurologylive.com/view/episode...

🏆 The #NeuroMadness Championship is here!

After weeks of polling, only one contender remains from each bracket:
#1 Natalizumab Vs. #2 OPERA 1 & 2 (MS)

One landmark therapy and one landmark clinical trial face off. Vote now to crown the champion‼️
#Neurology #MarchMadness #March

Positioning Gene Therapy in SMA: Insights From 64-Week STEER Study Outcomes | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Nazem Atassi, MD, SVP and Global Development Head of Neurology & Gene Therapy at Novartis, discussed 64-week STEER data and the evolving role of one-time gene therapy in SMA care.

🧬 New 64-week data from the STEER study highlight the potential durability of one-time gene therapy in #SMA

📈 Key outcomes
• +2.75 HFMSE improvement
• +2.93 RULM improvement
• 🚫 new safety signals

Expert insights from Nazem Atassi, MD ⬇️
www.neurologylive.com/view/positio...
#Neurology #GeneTherapy

🚨 The votes are IN!🚨

The #NeuroMadness Championship matchup is officially set 🧠🏀

After weeks of fierce competition, only TWO teams remain:
#1 Natalizumab will take on #2 OPERA I & II (MS) in the #Finals

Stay tuned for the final poll of the tournament 👀
#Neurology #MarchMadness #March #Clinical

Personalizing Patient Care and Addressing Invisible Disease Burden in Multiple Sclerosis | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Constance V. Katsafanas, DO, director of the Neurology Residency Program at the Marcus Neuroscience Institute, highlighted the importance of individualized treatment strategies in multiple sclerosis.

🧠 Living with #MS isn’t just about physical symptoms

Constance V. Katsafanas, DO, explores why personalized treatment strategies and addressing invisible symptoms are essential for improving patient outcomes

Read more: www.neurologylive.com/view/persona...
#Neurology #MSAwareness

What Clinicians Should Know About Extended Dosing of Pegunigalsidase Alfa | NeurologyLive - Clinical Neurology News and Neurology Expert Insights Rachele Berria, MD, PhD, Medical Affairs at Chiesi Global Rare Diseases, discussed the clinical data and implications of newly approved every-4-week dosing of pegunigalsidase alfa for Fabry disease in...

🧬 Fabry disease update ⬆️

The #EC has approved every-4-week dosing of pegunigalsidase alfa (Elfabrio) for adults with Fabry disease stable on ERT. Rachele Berria, MD, PhD, discusses the clinical implications.

Read more here 👉 www.neurologylive.com/view/what-cl...
#Neurology #ClinicalTrials

🚨 On to the #FinalFour in #NeuroMadness

Drug Classes:
#1 Natalizumab defeats #4 Gepants and will face #3 Anti-CGRP mAbs

Clinical Trials:
#6 SANAD (Epilepsy) upsets #1 AFFIRM (MS) and meets up with #2 OPERA I & II (MS)

Only 3 matchups remain so make sure to add your voice by voting! #Neurology

FDA Approves Higher Strength, More Effective Nusinersen Dose for Spinal Muscular Atrophy | NeurologyLive - Clinical Neurology News and Neurology Expert Insights The FDA has approved a higher-dose regimen of nusinersen for spinal muscular atrophy, supported by DEVOTE data showing improved motor outcomes, reduced neurodegeneration markers, and a safety profile ...

#Breaking: 🚨 The @fda.gov has approved a higher-dose regimen of nusinersen (Spinraza; Biogen) for Spinal Muscular Atrophy.

The high-dose regimen is expected to introduce a faster loading schedule for treatment-naïve patients.
Read more: www.neurologylive.com/view/fda-app...
#Neurology #FDA #SMA

🏀 #NeuroMadness continues on our LinkedIn and X pages as the #Elite8 tips off!

Be sure to follow us on LinkeIn (@NeurologyLive) and X (@neurology_live) to participate

Let us know which drug class or clinical trial changed the field more by casting your vote now❗
#Neurology #MarchMadness #Neuro

Celebrating our clients' media successes 🌟

1️⃣ @vygongroup.bsky.social in @lesechosfr.bsky.social. Acquired Stiletto®, boosting vascular access leadership.
2️⃣ PLL Therapeutics in @neurologylive.bsky.social. Positive stage I results of phase I/II trial in ALS.
#PR #biotech #medtech

Today is #PurpleDay! 💜 Awareness is the first step toward better care for the millions living with epilepsy. @curedravet.bsky.social

Stay informed with our coverage:

🔬 Exploring the POLARIS program for EXT101. 🔗 hubs.li/Q048tC-T0

🗣️ How can we better support those with DEEs? 🔗 hubs.li/Q048tGV20

🏀 #NeuroMadness Round 1 is finally complete!

Advancing in the Drug Classes bracket:
#1 Natalizumab - #2 S1P Modulators - #3 Anti-CGRP mAbs - #4 Gepants

Advancing in the Pivotal Trials bracket:
#1 AFFIRM - #2 OPERA I & II - #5 PROMISE-2 - #6 PALM

Stay tuned — the semifinal polls drop later today.

🚨 #BREAKING: The @fda.gov has approved Denalitx's Tividenofusp alfa-eknm (AVLAYAH)❗

The drug is indicated for treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II [ #MPSII ]) in pediatric patients.

#FDA #FDANews #DrugApproval #Neurology #Wow

ICYMI: Our new series Neuromuscular Insights with @ucsfhealth.bsky.social is live

Episode 1 breaks down long-term tofersen data in SOD1-ALS and why timing of treatment may matter

Featuring Drs. Lomen-Hoerth + Miller
🎧 Watch: www.neurologylive.com/view/toferse...